Survey on the Treatment of Anemia Using Recombinant Human Erythropoietin 2 (STAR-2)

• Status: Completed
• Trial end date: 2009-11-01
• Target enrollment: 0
• Participant gender: All

Summary

The main purpose of this study is to evaluate the safety and efficacy (% response) of epoetin alfa in the treatment of anemia in adults receiving chemotherapy for cancer.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Janssen-Cilag B.V.
• Treatments: Epoetin Alfa

Criteria

Inclusion Criteria:

• Patients with a diagnosis of solid tumors, multiple myeloma (Kahlers' disease), non-Hodgkin lymphoma or Hodgkins' disease

• Patients must already be receiving chemotherapy or start their first cycle within a week of enrollment

• Patients must receive epoetin alfa treatment (expected treatment duration is at least 4 weeks)

Exclusion Criteria:

• Patients who cannot read the Dutch language and/or do not understand the Dutch Informed Consent Form and patients participating in either of our observational studies, EVALUATE or COMPARE